Loading…
Loading…
LUND, SE / ACCESS Newswire / April 29, 2026 / BioInvent International (STO:BINV) "During the first quarter of 2026, our strategy remained centered on efficient resource allocation across our most advanced assets, BI-1808 (anti-TNFR2) and BI-1206 (anti-FcγRIIB), with the goal of advancing these innovative immune-modulatory antibodies for patients who urgently need better treatment options."- Martin Welschof, CEO of BioInvent.
LUND, SE / ACCESS Newswire / February 26, 2026 / BioInvent International (STO:BINV) - "During 2025 we sharpened our clinical focus and resource allocation to accelerate our most advanced assets, BI-1808 (anti-TNFR2) and BI-1206 (anti-FcγRIIB), while pausing earlier programs to maximize the probability of success and near-term value creation."- Martin Welschof, CEO BioInvent.
LUND, SWEDEN / ACCESS Newswire / February 27, 2025 / BioInvent International (STO:BINV) "2024 was a year with several exciting developments reported from across our broad portfolio of clinical programs. We now have two Phase 2 and four Phase 1 trials running in our six clinical programs leveraging the TNFR2 and FcyRIIB targets.
LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International (STO:BINV) The first two patients enrolled in the Phase 2a study triplet arm combining BI-1206 with rituximab and Calquence® responded to treatment One complete response (CR) and one partial response (PR) The treatment has been well-tolerated with no safety or tolerability concerns Study now expanding to additional clinical investigational sites and patient enrollment on track with further Phase 2a results expected by mid-2025 BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces promising initial clinical response data from the two enrolled patients in the triple combination arm of the Phase 1/2a study of its anti-FcyRIIB antibody, BI-1206, combined with rituximab and AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor Calquence® (acalabrutinib), in non-Hodgkin's lymphoma (NHL). The preliminary data demonstrates that the combination treatment is well tolerated with the two enrolled patients already showing clinical responses.
Brandes International might as well use the tag line "we buy ugly stocks." They are a deep contrarian value manager. The firm's success dates back to last century, and it investment success over the decades made it founder a billionaire philanthropist. Top value investors like Charles Brandes and John Templeton focused on buying portfolios of non-US stocks with low turnover for long-term compounding returns.
LUND, SWEDEN / ACCESSWIRE / July 22, 2024 / BioInvent International (STO:BINV) Two posters to be presented on early clinical projects from BioInvent's robust pipeline totaling six clinical programs: Progress with the Phase 1 trial studying BI-1910 as single agent in solid tumors Initial clinical data from the BT-001 Phase 1 study evaluating the candidate both as single agent and in combination with KEYTRUDA® (pembrolizumab) in patients with solid tumors European Society for Medical Oncology (ESMO 2024) to be held September 13-17, 2024 BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced abstracts for BI-1910 and BT-001 have been selected for presentation at ESMO 2024, being held in Barcelona, Spain from September 13th to 17th, 2024. BI-1910 is a monoclonal antibody, a TNFR2 agonist, currently enrolling patients in the monotherapy part of the ongoing Phase 1/2a study in patients with advanced solid tumors.
Panagora Asset Management Inc. cut its position in ACCO Brands Co. (NYSE:ACCO – Free Report) by 0.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 536,919 shares of the industrial products company’s stock after selling 4,912 shares during the quarter. Panagora Asset Management Inc. owned 0.57% of ACCO Brands worth $3,264,000 as of its most recent SEC filing. Other hedge funds have also recently made changes to their positions in the company. WINTON GROUP Ltd boosted its position in ACCO Brands by 15.1% during the 3rd quarter. WINTON GROUP Ltd now owns 17,172 shares of the industrial products company’s stock worth $99,000 after buying an additional 2,255 shares during the period. Exchange Traded Concepts LLC lifted its holdings in shares of ACCO Brands by 3.6% during the fourth quarter. Exchange Traded Concepts LLC now owns 69,312 shares of the industrial products company’s stock worth $421,000 after purchasing an additional 2,424 shares during the period. DMC Group LLC grew its stake in shares of ACCO Brands by 13.8% in the fourth quarter. DMC Group LLC now owns 20,276 shares of the industrial products company’s stock worth $123,000 after purchasing an additional 2,459 shares during the last quarter. AXQ Capital LP increased its holdings in ACCO Brands by 34.8% in the third quarter. AXQ Capital LP now owns 16,770 shares of the industrial products company’s stock valued at $96,000 after purchasing an additional 4,332 shares during the period. Finally, Wedge Capital Management L L P NC raised its position in ACCO Brands by 8.8% during the 4th quarter. Wedge Capital Management L L P NC now owns 82,879 shares of the industrial products company’s stock worth $504,000 after purchasing an additional 6,738 shares during the last quarter. 84.56% of the stock is owned by institutional investors and hedge funds. ACCO Brands Stock Performance ACCO stock opened at $5.15 on Monday. The firm has a market cap of $492.34 million, a PE ratio of -19.07, a price-to-earnings-growth ratio of 0.40 and a beta of 1.66. The company has a current ratio of 1.69, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. The stock has a 50-day moving average price of $5.18 and a 200-day moving average price of $5.56. ACCO Brands Co. has a 1-year low of $4.64 and a 1-year high of $6.62. ACCO Brands (NYSE:ACCO – Get Free Report) last announced its quarterly earnings data on Friday, May 3rd. The industrial products company reported $0.03 EPS for the quarter, topping the consensus estimate of $0.02 by $0.01. The company had revenue of $358.90 million during the quarter, compared to the consensus estimate of $371.80 million. ACCO Brands had a negative net margin of 1.36% and a positive return on equity of 12.42%. The company’s quarterly revenue was down 10.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.09 EPS. As a group, equities research analysts expect that ACCO Brands Co. will post 1.07 earnings per share for the current year. ACCO Brands Dividend Announcement The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 12th. Stockholders of record on Friday, May 17th will be issued a dividend of $0.075 per share. The ex-dividend date is Thursday, May 16th. This represents a $0.30 annualized dividend and a dividend yield of 5.83%. ACCO Brands’s dividend payout ratio is -111.11%. Insider Buying and Selling In related news, SVP Angela Y. Jones sold 15,000 shares of the company’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $4.96, for a total value of $74,400.00. Following the sale, the senior vice president now owns 18,621 shares in the company, valued at approximately $92,360.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 7.30% of the stock is owned by company insiders. Analyst Ratings Changes ACCO has been the topic of a number of analyst reports. StockNews.com lowered ACCO Brands from a “buy” rating to a “hold” rating in a research report on Monday, May 6th. Barrington Research reissued an “outperform” rating and set a $7.50 target price on shares of ACCO Brands in a research report on Thursday, February 29th. Get Our Latest Stock Analysis on ACCO About ACCO Brands (Free Report) ACCO Brands Corporation designs, manufactures, and markets consumer, school, technology, and office products. It operates through three segments: ACCO Brands North America, ACCO Brands EMEA, and ACCO Brands International. The company provides computer and gaming accessories, planners, dry erase boards, school notebooks, and janitorial supplies; storage and organization products, such as lever-arch binders, sheet protectors, and indexes; sheet protectors and indexes; laminating, binding, and shredding machines; writing instruments and art products; stapling and punching products; and do-it-yourself tools.
Firms should offer ETF products because investor demand is not slowing down, according to one Goldman Sachs ETF expert.
SEC filings for BINV aren't indexed yet — common for recently launched funds. Browse the issuer's filings on SEC EDGAR directly.